Axogen Inc vs C.H. Robinson Worldwide, Inc. — how do they compare? Axogen Inc trades at $48.56 (market cap $2.61B), while C.H. Robinson Worldwide, Inc. trades at $146.72 (market cap $16.96B). The key difference: C.H. Robinson Worldwide, Inc. is far larger — about 6.5× Axogen Inc's market cap, and C.H. Robinson Worldwide, Inc. pays a 1.74% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | CHRW | |
|---|---|---|
Market Cap | $2.61B | $16.96B |
Sector | Technology | Industrials |
52-Week High | $48.48 | $209.42 |
52-Week Low | $14.16 | $118.77 |
Enterprise Value | $2.52B | $18.78B |
Dividend Yield | — | 1.74% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $48.53, up 0.64% today, with a bullish technical signal from moving averages and strong analyst support. Q2 2026 revenue grew 23.1% to $69.7M, beating estimates, and full-year guidance was raised to at least $279M. However, the company remains unprofitable with a net income margin of -13.36% and negative ROE, reflecting high SG&A costs relative to revenue.
The outlook is mixed: robust revenue growth and FDA-backed nerve care platform expansion offer upside, but persistent losses and high valuation multiples (P/S 9.57) pose risks. With 84% analyst buy ratings and a $54.33 price target, near-term momentum depends on execution toward profitability amid competitive and reimbursement pressures.
CHRW trades at $148.29, down 0.71% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company has beaten EPS estimates for the last three quarters, with Q3 2026 expected at $1.65. Revenue for 2025 was $16.23B, with net income of $587.08M and a profit margin of 3.61%. Recent news includes the declaration of a quarterly dividend and participation in industry summits.
The outlook is mixed: strong profitability metrics like a 37.12% ROE and analyst consensus price target of $193.00 suggest upside, but bearish technicals and a high P/E of 27.7 indicate valuation concerns. Risks include freight demand volatility and legal challenges, as seen with the Dallas verdict appeal. Institutional buying activity provides support, but investors should weigh growth against current market sentiment.
Trailing returns across standard periods
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →